In 2019, the American Society for Gastrointestinal Endoscopy (ASGE) published revised guidelines that attempted to risk stratify the likelihood of choledocholithiasis based on clinical predictors including age, LFT derangement, total bilirubin, presence of cholangitis, imaging reporting a dilated CBD or the presence of choledocholithiasis. This evidence concerns the gene OPN1MW and cholangitis.